Could a common diabetes pill strengthen the failing right heart in PAH patients?
NCT ID NCT06992440
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 26 times
Summary
This study tests whether empagliflozin, a drug already used for diabetes, can improve right heart function in 78 adults with pulmonary arterial hypertension (PAH). Participants continue their usual PAH medications and are randomly assigned to receive either empagliflozin or a placebo. The main goal is to see if the drug increases the heart's pumping ability, measured by MRI, over the study period.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
The Johns Hopkins Hospital
Baltimore, Maryland, 21287, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.